Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) on Sunday presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance of evaluating the broad burden of migraine beyond headache and migraine frequency.

According to the company, the patient-reported outcomes data highlight the opportunity to focus on elements of migraine burden that are meaningful to individuals living with migraine and report improvement of migraine-related cognitive symptoms after eptinezumab treatment.

VYEPTI (eptinezumab) is a humanised monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The drug was developed for administration by intravenous (IV) infusion to deliver 100% of the medication into the bloodstream at the end of the infusion.

The study demonstrated that migraine-related cognitive symptoms are highly prevalent and bothersome among patients at baseline. Symptoms that were considered moderately to extremely bothersome -- such as difficulty making decisions, difficulty with reading comprehension, difficulty with complex tasks, and brain fog (difficulty concentrating/focusing, trouble finding right words/speaking, mental cloudiness) -- were reported by 64.7%, 60.0%, 62.6%, and 82.1% of participants, respectively. This population, characterised by a high disease impact, reported improvements following treatment with eptinezumab. Across individual cognitive symptoms (brain fog, difficulty making decisions, difficulty with reading comprehension and difficulty with complex tasks), more than 50% of participants reported improvements at 6 months (after two doses of eptinezumab) compared to baseline, with marked improvements observed as early as Day 7 post-treatment.

VYEPTI (eptinezumab-jjmr) was approved by the US Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorisation by the European Commission for the prophylaxis of migraine in adults who have at least four migraine days per month. It is now available in more than 30 markets worldwide.